Jinghua Weikang Capsule Containing Quadruple Therapy for IgAN With Helicobacter Pylori Infection

Peking University

Status

Invitation-only

Conditions

Helicobacter Pylori Infection

Treatments

Drug: JWC containing quadruple therapy

Drug: Bismuth-containing quadruple therapy

Study type

Interventional

Funder types

Other

Identifiers

NCT05320133

2021CR36

Details and patient eligibility

About

This study is to evaluate the efficacy and safety of the Jinghua Weikang Capsule (a Chinese patent medicine for peptic ulcer and gastritis) containing quadruple therapy (Jinghua Weikang Caplsule plus triple therpy) for eradicating Helicobacter pylori in IgA nephropathy.

Enrollment

80 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

IgA nephropathy diagnosed by renal biopsy;
Current Helicobacter pylori infection;
Age 18-65.

Exclusion criteria

①eGFR<90ml/（min·1.73m2）-
History of Helicobacter pylori treatment
Present taking hormones or immunosuppressants
Malignant tumor and high-grade intraepithelial neoplasia and severe dysplasia of gastric mucosa
Allergy history to medicines used in the study
History of gastric surgery
Uncontrolled chronic diseases such as diabetes, cardiovascular and cerebrovascular diseases, respiratory diseases, mental disorders and other researchers are considered to affect treatment and assessment
Combined with other primary or secondary nephropathy except for IgAN
Combined with acute renal injury
Female patients with pregnancy, lactation and planned pregnancy.